Executive Summary
PharmaCyte Biotech’s QQ1 2025 results depict a divergent picture: operating performance remains cautious with an advance into loss territory on the operating line, while reported net income is boosted by a sizable non-operating gain. The company posted an operating loss of $1.27 million and negative operating cash flow of $0.37 million, yet reported net income of $23.42 million driven by $24.69 million of total other income and a meaningful non-cash item. The quarter also featured substantial financing activity, including a stock repurchase program of $10.17 million and $7.00 million of investments, contributing to an overall cash burn of $17.54 million. On the balance sheet, PharmaCyte displayed a solid liquidity position with $32.64 million in cash, $29.12 million in long-term investments, and a stockholders’ equity base of $53.04 million, alongside a net cash position of $32.64 million. While liquidity appears robust for near-term needs, the results underscore a material reliance on non-operating items for profitability and ongoing cash burn from operations. Investors should focus on pipeline progress, potential licensing deals, and any changes in working capital or financing activity that could materially affect liquidity and the path to revenue generation.
Key Performance Indicators
QoQ: 1 638.78% | YoY:835.83%
QoQ: 1 017.65% | YoY:451.85%
Key Insights
Overview of key metrics observed in QQ1 2025: Revenue: N/A; Operating income: -$1.27 million (YoY +38.85%, QoQ +59.92%); Net income: $23.42 million (YoY +835.83%, QoQ +1,638.78%); EBITDA: -$1.27 million; EPS: $1.90; Cash from operations: -$0.37 million; Free cash flow: -$0.37 million; Cash and equivalents: $32.64 million; Total assets: $70.19 million; Total liabilities: $17.15 million; Stockholders’ equity: $53.04 million; Current ratio: 4.40; Quick ratio: 4.40; Net debt: -$32.64 million; Weig...
Financial Highlights
Overview of key metrics observed in QQ1 2025: Revenue: N/A; Operating income: -$1.27 million (YoY +38.85%, QoQ +59.92%); Net income: $23.42 million (YoY +835.83%, QoQ +1,638.78%); EBITDA: -$1.27 million; EPS: $1.90; Cash from operations: -$0.37 million; Free cash flow: -$0.37 million; Cash and equivalents: $32.64 million; Total assets: $70.19 million; Total liabilities: $17.15 million; Stockholders’ equity: $53.04 million; Current ratio: 4.40; Quick ratio: 4.40; Net debt: -$32.64 million; Weighted average shares: 7.87 million; Valuation signals show price-to-earnings around 0.17 and price-to-book around 0.29, underscoring a market view of limited near-term profitability and potential upside if pipeline milestones materialize.
Income Statement
| Metric |
Value |
YoY Change |
QoQ Change |
| Operating Income |
-1.27M |
38.85% |
59.92% |
| Net Income |
23.42M |
835.83% |
1 638.78% |
| EPS |
1.90 |
451.85% |
1 017.65% |
Key Financial Ratios
operatingCashFlowPerShare
$-0.05
freeCashFlowPerShare
$-0.05
Management Commentary
No earnings call transcript is provided in the dataset. As a result, there are no management quotes or thematic highlights to quote or group by specific strategic themes. The analysis below relies on disclosed financials and typical sector considerations for a late-stage biotech with an early-stage revenue profile.
Forward Guidance
No explicit forward guidance is disclosed in the provided data. Given PharmaCyte’s liquidity cushion and ongoing investments in long-term assets, the company may prioritize preserving runway while pursuing licensing, collaboration, or partnership opportunities around its CellinaBox platform. Investors should monitor any management commentary on anticipated clinical milestones, partnering activity, and cost-control initiatives that could extend liquidity and unlock future revenue-generation potential.